The Peptide Field
Menu

7 FDA label and trial tables · Checked

Less hunger vs placebo, out of 100 people

Mounjaro label

Placebo1%
On Mounjaro (by dose)5% to 11%

In the Mounjaro label, 5% to 11% on Mounjaro (by dose) had less appetite. On placebo, 1% did.

See all 7 tables

Every table that lists less hunger

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

FDA-approved medicines

MounjaroFDA-approved product

Mounjaro trials in adults with type 2 diabetes

Row in the source: Less appetite

Placebo1%
On Mounjaro (by dose)5% to 11%
Who was studied
Adults with type 2 diabetes in 2 trials. One tested Mounjaro alone. The other added it to long-acting insulin, with or without metformin. 718 adults took Mounjaro in three dose groups and 235 took placebo.
How long
40 weeks
Source
Mounjaro prescribing information on DailyMed . FDA label revised August 2026.

VictozaFDA-approved product

Victoza trials in adults with type 2 diabetes

Row in the source: Less hunger

Placebo1%
On Victoza (by dose)9% to 10%
Who was studied
Adults with type 2 diabetes in 5 trials. The table counts 1,669 adults on Victoza in two dose groups and 661 on placebo.
How long
At least 26 weeks each
Source
Victoza prescribing information on DailyMed . FDA label revised October 2025.

Medicines that are not FDA-approved

CagrilintideNo FDA-approved product

Phase 2 weight trial (NCT03856047)

Row in the source: Less hunger

Placebo4.0%
On cagrilintide (by dose)4.0% to 16.8%
Who was studied
706 adults without diabetes who had obesity, or overweight with high blood pressure or unhealthy blood-fat levels. 506 got cagrilintide and 101 got placebo. A liraglutide group of 99 is not shown.
How long
26 weeks of treatment, side effects counted to week 32
Source
ClinicalTrials.gov posted results . Trial registry results posted July 18, 2023.

RetatrutideNo FDA-approved product

TRIUMPH-2

Row in the source: Less hunger

Placebo4.5%
On retatrutide (by dose)5.8% to 17.1%
Who was studied
Adults with type 2 diabetes and obesity or overweight.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-3

Row in the source: Less hunger

Placebo3.0%
On retatrutide (by dose)13.5% to 14.5%
Who was studied
Adults with severe obesity and heart or blood vessel disease, with or without type 2 diabetes.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

Phase 2 obesity trial (NCT04881760)

Row in the source: Less hunger

Placebo8.6%
On retatrutide (by dose)11.4% to 31.4%
Who was studied
338 adults with obesity, or with overweight and a health problem linked to weight.
How long
48 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted September 13, 2023.

RetatrutideNo FDA-approved product

Phase 2 type 2 diabetes trial (NCT04867785)

Row in the source: Less hunger

Placebo0%
On retatrutide (by dose)4.3% to 20.8%
Who was studied
281 adults with type 2 diabetes. This trial also had a dulaglutide group, which is not shown.
How long
36 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted July 3, 2023.

How long were people watched?

Each bar is one set of trials. The dots on this page come only from the time inside each bar.

Stated length Range in the source No end date given

  1. Mounjaro, adults with type 2 diabetes40 weeks

  2. Victoza, adults with type 2 diabetesAt least 26 weeks each

  3. Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32

  4. Retatrutide, TRIUMPH-280 weeks

  5. Retatrutide, TRIUMPH-380 weeks

  6. Retatrutide, phase 2 (obesity)48 weeks

  7. Retatrutide, phase 2 (diabetes)36 weeks

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?